Epiphany Investing

Searching Out the Optimal Portfolio of “Revelation” Stocks

Amgen Reminds Us of Its Biotech Bloodlines; Analyst Day Notes (AMGN)

Amgen (AMGN) is one of the founding fathers of biopharma, but after showing its age in recent years with slowing drug sales and swirling safety concerns, share valuations have fallen dramatically from the high-20’s level Amgen once commanded.
We haven’t treated this company like a biotech in a long time, but Amgen is actually trading up [...]

A Hungry Blind Man at the Buffet

These are the days that make investors - and economists - and analysts - try to pull their hair out. I suppose some succeed. It’s not that we can’t handle down days; our skin is impervious to them now. But a day like today is rife with contradiction, uncertainty, changing rules, and low rates of [...]

Dipping into Big Pharma on Hunt for Yield

After spending the past few days reviewing my old friends in Big Pharma (MRK, PFE, SGP, LLY, BMY, NVS) I am struck by how much pessimism reigns over the industry. Yes, there are always the occasional big multiple stocks with a current compound driving expectations…but on the whole, valuations are low, cash and balance sheets [...]